These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14723959)

  • 21. A "cephalosporin-like" cyclic depsipeptide: synthesis and reaction with beta-lactam-recognizing enzymes.
    Adediran SA; Cabaret D; Pratt RF; Wakselman M
    Bioorg Med Chem Lett; 1999 Feb; 9(3):341-6. PubMed ID: 10091681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Syntheses and kinetic evaluation of racemic and optically active 2-benzyl-2-methyl-3,4-epoxybutanoic acids as irreversible inactivators for carboxypeptidase A.
    Lee M; Kim DH
    Bioorg Med Chem; 2002 Apr; 10(4):913-22. PubMed ID: 11836098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Approach to Clavams and 1-Oxacephams from Hydroxy Acids.
    Furman B; Kaluza Z; Chmielewski M
    J Org Chem; 1997 May; 62(10):3135-3139. PubMed ID: 11671696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleophilic re-activation of the PC1 beta-lactamase of Staphylococcus aureus and of the DD-peptidase of Streptomyces R61 after their inactivation by cephalosporins and cephamycins.
    Faraci WS; Pratt RF
    Biochem J; 1987 Sep; 246(3):651-8. PubMed ID: 3500712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphonamidate analogues of dipeptides with carboxypeptidase A and beta-lactamase-inhibitory activity: elucidation of the mechanism of beta-lactamase inhibition by electrospray mass spectrometry.
    Payne DJ; Bateson JH; Tolson D; Gasson B; Khushi T; Ledent P; Frère JM
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):457-61. PubMed ID: 8670057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and beta-lactamase inhibitory activities of some clavulanic acid analogues.
    Mak CP; Prasad K; Turnowsky F
    J Antibiot (Tokyo); 1983 Apr; 36(4):398-406. PubMed ID: 6602120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro pharmacodynamic simulation of clavulanic acid concentrations: effect on Staphylococcus aureus and Haemophilus influenzae beta-lactamase activity.
    Martín M; Aguilar L; Balcabao IP; Gómez-Lus ML; Dal-Ré R; Prieto J
    J Antimicrob Chemother; 1997 Feb; 39(2):290-2. PubMed ID: 9069559
    [No Abstract]   [Full Text] [Related]  

  • 30. Classification of beta-lactamase-producing bacteria.
    Sutherland R
    Scott Med J; 1982; 27 Spec No.():S3-9. PubMed ID: 6984779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Des-, syn- and anti-oxyimino-delta 3-cephalosporins. Intrinsic reactivity and reaction with RTEM-2 serine beta-lactamase and D-alanyl-D-alanine-cleaving serine and Zn2+-containing peptidases.
    Laurent G; Durant F; Frere JM; Klein D; Ghuysen JM
    Biochem J; 1984 Mar; 218(3):933-7. PubMed ID: 6609701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial production of carbapenems and clavams: evolution of beta-lactam antibiotic pathways.
    McGowan SJ; Bycroft BW; Salmond GP
    Trends Microbiol; 1998 May; 6(5):203-8. PubMed ID: 9614345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereoselective inhibition of glutamate carboxypeptidase by chiral phosphonothioic acids.
    Lu H; Berkman CE
    Bioorg Med Chem; 2001 Feb; 9(2):395-402. PubMed ID: 11249132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological profiling of parthenolide ether analogs.
    Freund RRA; Gobrecht P; Moser P; Fischer D; Arndt HD
    Org Biomol Chem; 2019 Dec; 17(45):9703-9707. PubMed ID: 31701984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors.
    Mascaretti OA; Danelon GO; Laborde M; Mata EG; Setti EL
    Curr Pharm Des; 1999 Nov; 5(11):939-53. PubMed ID: 10539998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Origin of chiral pharmacology: stereochemistry in metalloprotease inhibition.
    Kim DH
    Mini Rev Med Chem; 2001 Jul; 1(2):155-61. PubMed ID: 12369980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
    Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and evaluation of ketophosph(on)ates as beta-lactamase inhibitors.
    Perumal SK; Pratt RF
    J Org Chem; 2006 Jun; 71(13):4778-85. PubMed ID: 16776502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemistry and action of clavulanic acid.
    Cole M
    Scott Med J; 1982; 27 Spec No.():S10-6. PubMed ID: 6762660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thioxophosphoranyl aryl- and heteroaryloxiranes as the representants of a new class of metallocarboxypeptidase inhibitors.
    Fernández D; Illa O; Avilés FX; Branchadell V; Vendrell J; Ortuño RM
    Bioorg Med Chem; 2008 May; 16(9):4823-8. PubMed ID: 18396051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.